Cases
Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM)
Securities Class Action
Overview
Overview
- Date:
- 4/2/2018
- Company Name:
- Bellicum Pharmaceuticals, Inc.
- Stock Symbol:
- BLCM
- Class Period:
- FROM 5/8/2017 TO 1/30/2018
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Southern District of Texas
NEW YORK, April 2, 2018 – Bragar Eagel & Squire, P.C. announces to investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of Texas on behalf of all persons or entities who purchased or otherwise acquired Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) securities between May 8, 2017 and January 30, 2018 (the “Class Period”). Investors have until April 9, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Bellicum operates as a clinical stage biopharmaceutical company. The Company focuses on discovering and developing novel cellular immunotherapies for various forms of cancer.
The Company’s lead clinical product candidate, BPX-501, is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation. Bellicum has represented that BPX-501 is currently being evaluated in multiple Phase 1/2 clinical trials.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) a substantial undisclosed risk of encephalopathy was associated with the Company’s lead product candidate BPX-501; and (ii) as a result of the foregoing, Bellicum’s public statements were materially false and misleading at all relevant times.
On January 30, 2018, post-market, Bellicum issued a press release entitled “Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States,” announcing that it had “received notice from the U.S. Food and Drug Administration that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.”
On this news, Bellicum’s share price fell $2.12, or 25.85%, to close at $6.08 on January 31, 2018.
If you purchased or otherwise acquired Bellicum securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
Bellicum operates as a clinical stage biopharmaceutical company. The Company focuses on discovering and developing novel cellular immunotherapies for various forms of cancer.
The Company’s lead clinical product candidate, BPX-501, is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation. Bellicum has represented that BPX-501 is currently being evaluated in multiple Phase 1/2 clinical trials.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) a substantial undisclosed risk of encephalopathy was associated with the Company’s lead product candidate BPX-501; and (ii) as a result of the foregoing, Bellicum’s public statements were materially false and misleading at all relevant times.
On January 30, 2018, post-market, Bellicum issued a press release entitled “Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States,” announcing that it had “received notice from the U.S. Food and Drug Administration that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.”
On this news, Bellicum’s share price fell $2.12, or 25.85%, to close at $6.08 on January 31, 2018.
If you purchased or otherwise acquired Bellicum securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.